Targeting Inflammation: A New Frontier in Heart Disease Treatment

Traditionally, cholesterol and blood pressure control have been the backbone of cardiovascular disease prevention. However, recent breakthroughs have revealed that inflammation plays a central role in the development and progression of heart disease—even in people with normal cholesterol levels.

One of the biggest milestones in this area was the approval of colchicine, a low-cost anti-inflammatory drug, which has shown to reduce the risk of cardiovascular events by up to 30%. Colchicine, commonly used for gout, works by suppressing the inflammatory response involved in atherosclerosis (the buildup of plaques in arteries).


Other drugs, such as canakinumab and emerging biologics, are under investigation for their potential to specifically block key inflammatory pathways like IL-1β and CRP. These therapies could revolutionize how we manage patients who are at risk for heart attacks and strokes—even if they have no major lipid or blood pressure abnormalities.


This trend represents a paradigm shift in cardiology—from focusing only on mechanical and metabolic issues to addressing immune and inflammatory responses at the molecular level.

Why This Matters: Patients with "residual inflammatory risk" could benefit most.

These therapies open the door to precision cardiology—where treatments are tailored to the patient’s biological risk profile.

It also expands the toolkit for secondary prevention in those who have already had a heart attack.

To know more, visit: https://www.cardiology.scientexconference.com/

Comments

Post a Comment

Popular posts from this blog

Image
  Ventricular Assist Device – Miniature The treatment of individuals with severe heart failure has been transformed by the development of a ventricular assist device (VAD). When a donor heart cannot be identified, the VAD, which was initially designed as a bridge to transplantation , has been proved to extend life and improve quality of life. Older models needed patients to ambulate with hefty , huge external batteries and control devices and required the implantation of a big pump. Yet in the upcoming years, a number of ground-breaking advancements in device size , battery life, and even wireless charging technologies may render these devices physically undetectable and possibly reduce patient vulnerability to infections. The rates of haemolysis, thrombosis, and secondary aortic valve insufficiency have also been constrained by numerous mechanical improvements and newer operating paradigms. Cardiac Decellularization and Engineered Heart Tissue Promising new direction...
Read more
Image
Myocardial infarction events involving morality, incredibly high temperatures, and minute particles.  Myocardial infarction (MI) morbidity has been connected to extreme temperature events (ETEs), such as heat wave and cold spell, but their effects on MI mortality are less well understood. Although ambient fine particulate matter (PM2.5) and severe temperatures may work in concert to increase cardiovascular mortality , it is still unclear whether or how ETEs and PM2.5 interact to cause MI deaths.METHODS: To examine the relationship between exposure to ETEs and PM2.5 and MI mortality and assess their interacting effects, a time-stratified case-crossover study of 202 678 MI deaths in Jiangsu province, China, from 2015 to 2020 was conducted. Twelve ETE definitions were created using a variety of temperature thresholds and durations based on the perceived ambient temperature. In order to estimate daily ETEs and PM2.5exposures , values were taken from validated grid datasets at reside...
Read more

New Drug Nearly Eradicates “Stealth” Cholesterol (Lp(a)) – A Game‑Changer in Heart Disease Prevention

Image
A recent clinical trial reported in the New England Journal of Medicine and showcased at the American College of Cardiology revealed that lepodisiran—an experimental RNA-targeting drug—can reduce lipoprotein(a) [Lp(a)] by nearly 100% after a single dose, with sustained effects over a year 🔍 What You Need to Know Lp(a) is a genetically determined, stealth cholesterol that significantly raises the risk of heart attacks and strokes yet is not addressed by diet or standard statins. The Phase 2 trial, involving 320 participants across 10 countries, showed almost total Lp(a) suppression at 6 months, maintained at 1 year. Reported side effects were mild, primarily limited to injection-site reactions. No serious safety issues were found.                      🌍 Why This Matters This breakthrough could pave the way for targeted Lp(a) therapies—potentially reducing cardiovascular risk in over 1.4 billion people globally with elevated levels....
Read more